Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.80 USD

28.80
8,463,199

-0.29 (-1.00%)

Updated Sep 30, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

by Kinjel Shah

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory disease drug. AstraZeneca (AZN) to boost cell therapies portfolio with private company buyout.

Why Is Pfizer (PFE) Up 6.5% Since Last Earnings Report?

by Zacks Equity Research

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Novavax (NVAX) COVID Jab Gets Expanded Label in WHO's EUL

by Zacks Equity Research

The WHO updates Emergency Use Listing (EUL) for Novavax's (NVAX) COVID-19 vaccine to include its use as a primary series in adolescents and for use as a booster dose in adults.

Novavax (NVAX) Stock Nosedives 88% This Year: Here's Why

by Zacks Equity Research

Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Novavax (NVAX) Cancels COVID Jab Supply Deal With GAVI

by Zacks Equity Research

Novavax (NVAX) claims that GAVI's failure to procure its COVID vaccine doses is a reason to terminate the supply agreement. GAVI denies the company's claims and a legal battle is likely to follow.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Pfizer (PFE), BioNTech Provide New Data on BA.4/BA.5 Boosters

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccines show improved immune response against newer Omicron sublineages.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

by Zacks Equity Research

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

The Zacks Analyst Blog Highlights Pfizer, Goldman Sachs, General Electric, Microchip Technology and Genuine Parts

by Zacks Equity Research

Pfizer, Goldman Sachs, General Electric, Microchip Technology and Genuine Parts are included in this Analyst Blog.

Moderna's (MRNA) Omicron BA.4/5 Booster Jab Study Meets Goal

by Zacks Equity Research

Moderna's (MRNA) Omicron-targeting bivalent COVID vaccines exhibit substantial antibody response compared with an original booster dose of Spikevax.

Mark Vickery headshot

Top Analyst Reports for Pfizer, Goldman Sachs & General Electric

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Goldman Sachs Group, Inc. (GS) and General Electric Company (GE).

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine

by Zacks Equity Research

Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks

by Zacks Equity Research

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

by Zacks Equity Research

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Novavax (NVAX) Q3 Earnings Miss, Lowers '22 Sales Outlook

by Zacks Equity Research

Novavax (NVAX) reports mixed results in second-quarter 2022. Management lowers guidance for 2022.

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

by Zacks Equity Research

Sector ETF report for IYH

GSK's Q3 Earnings Beat, Ups 2022 Sales Outlook, Stock Up

by Zacks Equity Research

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises the full-year sales guidance for all its segment

Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth

by Zacks Equity Research

Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.

Stock Market News for Nov 2, 2022

by Zacks Equity Research

U.S. stocks ended lower for the second-straight session on Tuesday as better-than-expected economic data dimmed hopes of the Fed signaling a slower pace of interest rate hikes in the future after it announces another massive rate hike at the end of its two-day policy meeting starting on Wednesday.